Bg pattern

CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

CEVENFACTA 1 mg (45 kIU), powder and solvent for solution for injection

CEVENFACTA 2 mg (90 kIU), powder and solvent for solution for injection

CEVENFACTA 5 mg (225 kIU), powder and solvent for solution for injection

eptacog beta (activated)

This medicinal product is subject to additional monitoring, which will allow for the quick identification of new safety information. You can help by reporting any side effects you may get. The last section of the package leaflet contains information on how to report side effects.

Read all of this leaflet carefully before you start using this medicine, because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the package leaflet

  1. What is CEVENFACTA and what is it used for
  2. What you need to know before you use CEVENFACTA
  3. How to use CEVENFACTA
  4. Possible side effects
  5. Storage of CEVENFACTA
  6. Contents of the pack and further information
  7. Instructions for use of CEVENFACTA.

1. What is CEVENFACTA and what is it used for

CEVENFACTA contains the active substance eptacog beta (activated), a recombinant human coagulation factor VIIa (FVIIarh).

CEVENFACTA is used in adults and adolescents (12 years of age or older) who are born with haemophilia A or B and who have developed inhibitors (antibodies). It is used for:

  • treatment of bleeding episodes,
  • management of bleeding during surgery.

How CEVENFACTA works

This medicine works by forming a blood clot at the site of bleeding when the body's own clotting factors are not working.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use CEVENFACTA

Do not use CEVENFACTA

  • if you are allergic to eptacog beta (activated) or any of the other ingredients of this medicine (listed in section 6).
  • if you are allergic to rabbits or rabbit proteins.

Warnings and precautions

Before starting treatment with CEVENFACTA, tell your doctor:

  • If you have a history of atherosclerosis (when arteries become narrow due to disease), coronary artery disease (heart disease due to narrowing of the blood vessels that supply the heart), cerebrovascular disease (disease of the blood vessels that supply the brain), crush injury, sepsis (severe blood infection), or blood clots.
  • If you have heart disease, heart failure, or an abnormal heart rhythm.
  • If you have had a pulmonary embolism (in the lungs) or have undergone heart surgery.
  • If you have or have had any other medical problems.

Patients with a known allergy to casein may have a higher risk of hypersensitivity reactions. If signs or symptoms of hypersensitivity occur, treatment should be discontinued and medical attention should be sought immediately. Symptoms may include urticaria (itching with swelling under the skin), itching, rash, difficulty breathing, swelling around the mouth and throat, chest tightness, wheezing, dizziness or fainting, and low blood pressure.

Although not observed, the following reactions may occur with CEVENFACTA treatment:

  • Blood clots in the arteries of the heart (which can cause a heart attack or angina), in the brain (which can cause a stroke), or in the lungs or deep veins. Symptoms may include sweating and pain in the arms, legs, or abdomen, chest pain, difficulty breathing, loss of sensation or movement, and alteration of consciousness or speech.
  • Hypersensitivity or anaphylactic reactions. Symptoms may include urticaria (itching with swelling under the skin), itching, rash, difficulty breathing, swelling around the mouth and throat, chest tightness, wheezing, dizziness or fainting, and low blood pressure.
  • Inhibitors (antibodies) that can cause bleeding problems.

If you experience any of these reactions, consult your doctor before continuing to use CEVENFACTA.

It is important to record the batch number of your CEVENFACTA. Each time you use a new pack of CEVENFACTA, note the date and batch number (which appears on the pack, after 'Lot') and keep this information in a safe place.

Adolescents

The warnings and precautions mentioned apply to both adults and adolescents (12 years of age or older).

Other medicines and CEVENFACTA

Tell your doctor if you have recently taken or might take any other medicines.

You should consult your doctor before using CEVENFACTA if

  • you are taking or have recently taken another activated factor VII, activated or non-activated prothrombin complex concentrates,
  • you are taking or have recently taken factor XIII,

as the combination of these medicines with CEVENFACTA may increase the risk of thromboembolic events (formation of blood clots in the veins).

You should consult your doctor before starting treatment with CEVENFACTA with these medicines.

Pregnancy, breast-feeding, and fertility

If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.

Driving and using machines

Dizziness may occur after administration of CEVENFACTA. You should avoid driving or using machines while experiencing this symptom.

CEVENFACTA contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per injection, which is essentially 'sodium-free'.

3. How to use CEVENFACTA

Use of this medicine should be initiated and supervised by a doctor experienced in the treatment of haemophilia and/or bleeding disorders.

CEVENFACTA comes as a powder and must be reconstituted with solvent and injected into a vein (intravenous injection). Consult the instructions for use in the user guide at the end of this leaflet (section 7).

Self-administration

Injection of medicines requires special training. Do not attempt to self-administer unless your doctor or haemophilia treatment centre has taught you how to do it.

Many people with inhibitors learn to self-inject themselves or with the help of a family member. Once informed, you will need additional injection equipment, apart from your CEVENFACTA kit, to properly treat your bleeding episodes at home. Make sure you have all the necessary injection equipment before preparing the medicine for injection. This additional injection equipment will be provided by your healthcare professional (e.g. your pharmacist or haemophilia treatment centre).

CEVENFACTA can be injected at a haemophilia treatment centre, in your doctor's office, or at home. It is essential to treat bleeding as soon as possible to control it.

Start treatment of a bleeding episode as soon as possible, ideally within 2 hours.

? In case of mild or moderate bleeding (e.g. joint, superficial muscle, soft tissue, and mucous membranes), you should treat yourself as soon as possible, ideally at home.

? In case of severe bleeding (e.g. limb [arm or leg] bleeding or life-threatening bleeding, intracranial [in the skull] or gastrointestinal [in the stomach or intestine] bleeding), you should contact your doctor.

Severe bleeding is usually treated in the hospital, but the first dose of CEVENFACTA can be administered on the way to the medical facility.

Do not treat yourself for more than 24 hours without consulting your doctor.

? Each time you use this medicine, inform your healthcare professional as soon as possible.

? If bleeding is not controlled within 24 hours, contact your healthcare professional or emergency service immediately. You will usually need hospital assistance.

For reconstitution of the medicine before administration, follow the instructions in the Instructions for useat the end of this leaflet (section 7).

Inject the solution into the vein over 2 minutes or less.

Follow exactly the administration instructions of this medicine given by your doctor. If in doubt, consult your doctor again.

Dose

Your healthcare professional will tell you how much CEVENFACTA to use and when to administer the medicine based on your weight, condition, and type of bleeding.

Treatment of bleeding episodes

Treatment with this medicine should be started as soon as a bleeding episode occurs.

Mild and moderate bleeding:

Home treatment should not last more than 24 hours in case of mild to moderate bleeding episodes. Continuation of home treatment after 24 hours should only be considered after consultation at a haemophilia treatment centre.

Severe bleeding:

Seek immediate medical attention if signs or symptoms of severe bleeding occur at home.

To avoid any delay in treatment, the first dose can be administered on the way to the haemophilia treatment centre or doctor's office.

Follow exactly the administration instructions of the medicine contained in this leaflet or as indicated by your doctor. If in doubt, consult your doctor again.

Method of administration

For reconstitution of the medicine before administration and administration instructions, follow the instructions in the Instructions for useat the end of this leaflet (section 7).

If you use more CEVENFACTA than you should

If you use too much CEVENFACTA, go to your doctor immediately.

If you forget to use CEVENFACTA:

If you forget to use CEVENFACTA, consult your doctor.

If you have any further questions on the use of this medicine, ask your doctor.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Common side effects

(may affect up to 1 in 10 people)

  • Dizziness
  • Headache
  • Discomfort at the injection site
  • Haematoma at the injection site
  • Increased body temperature
  • Postoperative haematoma
  • Injection-related reaction

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of CEVENFACTA

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date is the last day of the month stated.

Store below 30°C.

Do not freeze.

Keep the vial in the outer packaging to protect it from light.

For reconstitution of CEVENFACTA, use only the material provided in the kit.

After reconstitution, the product should be stored in the vial and administered within 4 hours. Any remaining solution should be discarded 4 hours after reconstitution.

Do not use this medicine if you notice that the liquid contains particles or is cloudy after mixing.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the container and additional information

Composition of CEVENFACTA

  • The active ingredient is recombinant coagulation factor VIIa (eptacog beta (activated))
  • The other excipients are:

Powder: arginine hydrochloride, isoleucine, sodium citrate dihydrate, glycine, lysine hydrochloride, polysorbate 80, hydrochloric acid (for pH adjustment).

Solvent: water for injectable preparations.

See section 2 "CEVENFACTA contains sodium"

The powder for injectable solution contains: 1 mg/vial (which corresponds to 45 kIU/vial), 2 mg/vial (which corresponds to 90 kIU/vial), 5 mg/vial (which corresponds to 225 kIU/vial).

After reconstitution, the concentration of the solution is approximately 1 mg/ml (45 kIU/ml) of eptacog beta (activated). 1 kIU is equal to 1,000 IU (International Units).

Appearance of CEVENFACTA and container contents

The powder vial contains a white to off-white lyophilized powder and the pre-filled syringe of solvent contains a clear and colorless solution. The reconstituted solution should be clear or slightly opaque.

Each package of CEVENFACTA contains:

  • 1 glass vial with powder for an injectable solution,
  • 1 sterile vial adapter for reconstitution, equipped with a 5 µm filter,
  • 1 pre-filled syringe with water for injections,
  • 1 plunger rod with rear stop.

Presentation: 1 mg (45 kIU), 2 mg (90 kIU), and 5 mg (225 kIU).

Marketing authorization holder

Laboratoire français du Fractionnement et des Biotechnologies

Tour W

102 Terrasse Boieldieu, 19th Floor

92800 Puteaux

France

Manufacturer

LFB Biotechnologies

Zone d’activité de Courtaboeuf

3 Avenue des Tropiques

91940 Les Ulis

France

+33 1 69 82 70 10

You can request more information about this medication by contacting the local representative of the marketing authorization holder:

Date of the last revision of this leaflet:

Other sources of information

Detailed information about this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.

On the European Medicines Agency website, you can find this leaflet in all languages of the European Union/European Economic Area.

INSTRUCTIONS FOR USE

READ THESE INSTRUCTIONS CAREFULLY BEFORE STARTING TO USE CEVENFACTA

CEVENFACTA comes in the form of a powder. Before injection, it must be prepared (reconstituted) with the solvent supplied in the syringe. The solvent is water for injectable preparations. The reconstituted CEVENFACTA must be injected into a vein (for intravenous use only).

This kit provides the necessary equipment to reconstitute the medication. Additional materials are needed to inject the medication after reconstitution. These materials will be provided by your healthcare professional (e.g., your pharmacist or hemophilia treatment center).

Your doctor or nurse will show you and/or your caregiver how to prepare and inject CEVENFACTA. Do not use this kit without proper training from your healthcare professional or hemophilia treatment center.

Use a clean and germ-free (aseptic) technique when preparing and injecting the medication.

A CEVENFACTA kit contains:

  • 1 glass vial with powder for an injectable solution
  • 1 sterile vial adapter for reconstitution, equipped with a 5 µm filter
  • 1 pre-filled syringe with water for injectable preparations
  • 1 plunger rod with rear stop

Glass vial with white powder and label showing plastic cap and rubber stopper

Vial adapters for 1mg, 2mg, and 5mg with plastic covers and paper protectors showing spike and cap

Pre-filled syringe with solvent showing top end, thread, rear plastic stop, rubber piston, and Luer-Lock cap

You will also need a sterile injection set (butterfly needle and syringe), a sterile plastic syringe, alcohol-impregnated swabs, and a sharps container that complies with local regulations and guidelines. These materials are not included in the CEVENFACTA package.These materials will be provided by your healthcare professional (e.g., your pharmacist or hemophilia treatment center).

Infusion kit with syringe, alcohol swab, and sharps container

  1. Gather equipment and prepare the vial
  • Take out the number of CEVENFACTA kits you need to administer the prescribed dose, a sterile injection set (not supplied), and an alcohol swab (not supplied).

Do not use the kit if the security seal is broken or if there are signs that the kit is contaminated.Use a new one instead.

  • Check the expiration date on the side of the kit (Fig. A).

Do not use it after the expiration date.

CEVENFACTA vial with stylized eye and arrow pointing to batch information, serial number, and expiration date with letter A next to it

  • Check the name, concentration, and color of the box to ensure it contains the correct product (the 1 mg package is yellow, the 2 mg package is green, and the 5 mg package is purple).
  • Work on a clean and flat surface before starting the steps for reconstituting CEVENFACTA.
  • Wash your hands with soap and water and dry them with a clean towel or let them air dry (Fig. B).

Hand holding a white tablet under a stream of water coming out of a silver faucet

  • Take out the contents of a kit and an alcohol swab. Place everything on a clean surface (Fig. C).

Open box with vial and needle, arrow indicating removal, and device components on a white surface

  • Inspect all the items contained in the kit. Make sure each vial has a syringe of the same color.

Do not use the contents if it has been dropped or is damaged.Use a new kit instead.

  • Let the vial and pre-filled syringe reach room temperature if necessary. To do this, hold them until you feel them as warm as your hands.

Do not use the vial and pre-filled syringe heated in any other way.

  • Remove the plastic cap from the vial (Fig. D).

If the plastic cap is loose or the vial comes without a cap, do not use it.

Hand holding a medication vial with gray cap removed preparing for extraction

  • Clean the rubber stopper with an alcohol swab (Fig. E)and let it air dry for a few seconds to ensure it is as germ-free as possible.

Hands holding a vial and preparing to insert a needle with an alcohol pad to disinfect

  • After cleaning, avoid touching the rubber stopper with your fingers and do not let it come into contact with any other objectbefore placing the vial adapter, as this could contribute to the transmission of germs.
  1. Place the vial adapter
  • Remove the paper protective cover from the vial adapter package (Fig. F).

If the paper protector is not completely sealed or is broken, do not use the adapter.

Hand holding an injection device with exposed needle and visible spring, letter F in a black box

Do not remove the vial adapter from its protective package with your fingers.If you touch the adapter spike with your fingers, you may transmit germs.

  • Place the vial on a clean and flat surface and hold it with one hand. With the other hand, place the plastic cover (with the vial adapter inside) directly over the vial and insert the adapter spike into the center of the gray rubber stopper.
  • Press down firmly so that the adapter spike is inserted into the rubber stopper (you may hear and/or see it click into place) (Fig. G).

Hand holding an injection device with exposed needle and arrow indicating direction of insertion into skin

  • Remove the plastic package from the adapter by pressing lightly and lifting it up (Fig. H).

Hands holding an auto-injector with an arrow indicating the direction of injection towards a transparent vial

Once you have removed the plastic cover, do not touch the top of the adapter to avoid transmitting germs.

NOTE:The 5 mg vial adapter may not lie flat against the vial, but it is still fully functional. As mentioned earlier, your CEVENFACTA kit contains a single vial adapter (the one suitable for the vial included in the kit).

  1. Place the pre-filled syringe and insert the plunger rod
  • Remove the cap from the pre-filled syringe by holding the syringe body with one hand and using the other to unscrew it (turning to the left) (Fig. I).

Avoid touching the syringe tip to avoid transmitting germs from your fingers.

If the syringe cap is loose or the syringe comes without it, do not use it.

Auto-injector device with arrow indicating direction of injection on the forearm with the hand holding it

  • Hold the edges of the vial adapter and screw the pre-filled syringe by turning it to the right a few times until you feel resistance (Fig. J).

Be careful not to overtighten, as you will need to remove the syringe later.

Syringe with attached needle withdrawing liquid from a transparent vial with curved arrows indicating direction

  • To insert the plunger rod into the syringe, hold the top end of the plunger rod with one hand and the syringe body with the other.
  • Insert the plunger rod into the syringe and then screw it with a few turns (turning to the right) to secure it to the gray rubber piston of the syringe (Fig. K).

Hand holding a syringe turning to connect to a transparent vial with liquid and gray stopper on a flat surface, letter K in a black box

  1. Mix the medication in the vial
  • Slowly push the plunger rod all the way down to the bottom of the syringe to inject all the liquid from the syringe into the vial (Fig. L).

Do not push too quickly, as this may cause excessive foam and air to form in the vial.

Hand holding a transparent syringe with liquid and pushing the plunger down over a labeled vial, letter L

  • Gently rotate the vial or carefully roll it between your hands to dissolve all the powder (Fig. M).

Do not shake the vial, as this may cause foam and air to form.

Two hands holding vials with needles, curved arrows indicating gentle agitation, and letter M in a black circle

  • Visually inspect the final solution (Fig. N)to ensure it is clear or slightly opaque. All the powder should be dissolved, and there should be no particles floating in the liquid.

Do not use the product if the solution contains any particles or is cloudy after mixing.Repeat the process with a new kit.

Medication vial with an arrow pointing from an eye to the inside of the vial with a barcode and letter N

  1. Remove the empty syringe from the vial adapter
  • Without putting any medication back into the syringe, unscrew it from the vial adapter (turning to the left) until it is completely removed (Fig. O).

Hand holding a syringe withdrawing medication from a transparent vial with arrows indicating upward direction

  • Dispose of the empty syringe in an authorized sharps container (Fig. P).

Do not remove the vial adapter.

Do not touch the top of the adapter with the Luer-Lock closure. If you touch it, you may transmit germs from your fingers.

Hand holding a syringe over a biological waste container with a hazard symbol and sharps label

  1. Mix the vial (or vials) and inject the dose
  • If your dose requires more than one vial, repeat the previous steps with additional kits until you have the required dose.
  • Withdraw the liquid medication from the vial (or vials) using a sterile syringe provided by your pharmacy that is large enough to hold the prescribed dose.
  • CEVENFACTA must be administered within 4 hours after reconstitution (Fig. Q).

Do not use if more than 4 hours have passed since reconstitution.

Analog clock showing approximately 10:10 with the top half shaded and text indicating injection within 4 hours

  • CEVENFACTA can be used for intravenous injection of 2 minutes or less in a vein, as directed by your healthcare professional.
  1. Dispose of empty medication vials
  • After reconstitution and injection, safely dispose of the vial with its adapter, the injection syringe, and any other disposable material in an authorized sharps container (Fig. R).

Do not throw away in household trash.

Do not separate the vial from the vial adapter before disposing of them.

Do not reuse any of the items contained in the kit.

Hand holding an injection device over a biological waste container with a biohazard symbol and letter R

Follow local regulations and guidelines for the proper disposal of the sharps container.

Storage

CEVENFACTA comes in a kit that should be stored below 30°C.

Do not open the items in the kit until you are ready to use them.

Do not freeze or store in syringes that contain the reconstituted CEVENFACTA solution.

Avoid exposing the reconstituted CEVENFACTA solution to direct light.

Important information

CEVENFACTA is only injected into a vein (intravenous administration). Do not inject it by any other route, such as under the skin (subcutaneous) or into a muscle (intramuscular). Contact your doctor, nurse, or pharmacist if you have any problems.

Online doctors for CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Discuss questions about CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
The active ingredient in CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION is coagulation factor VIIa. This information helps identify medicines with the same composition but different brand names.
Who manufactures CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION is manufactured by Laboratoire Francais Du Fractionnement Et Des Biotechnologies. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to CEVENFACTA 2 MG (90 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
Other medicines with the same active substance (coagulation factor VIIa) include CEVENFACTA 1 mg (45 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION, CEVENFACTA 5 MG (225 KIU) POWDER AND SOLVENT FOR INJECTABLE SOLUTION, NOVOSEVEN 1 mg (50 KUI) POWDER AND SOLVENT FOR INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media